Glutathione-S-transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 13, Issue 1, 2007, Pages 57-64

  Stocco, Gabriele ^a   Martelossi, Stefano ^a   Barabino, Arrigo ^b   Decorti, Giuliana ^a   Bartoli, Flora ^a   Montico, Marcello ^c   Gotti, Annalisa ^a   Ventura, Alessandro ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

Author keywords

Adverse effects; Azathioprine; Genotyping; Glutathione S transferase; Inflammatory bowel disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMYLASE; AZATHIOPRINE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; MERCAPTOPURINE; METHYLTRANSFERASE; PRODRUG; THIOPURINE S METHYLTRANSFERASE; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; BLOOD SAMPLING; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CONTROLLED STUDY; CROHN DISEASE; DEMYELINATING DISEASE; DNA EXTRACTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; ENTERITIS; ENZYME ACTIVITY; ENZYME DEFICIENCY; FEMALE; GENE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; GLUCOSE TOLERANCE TEST; GST M1 GENE; GST P1 GENE; GST T1 GENE; HETEROZYGOTE; HUMAN; LEUKOPENIA; LIVER TOXICITY; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; NEUROPATHY; OPPORTUNISTIC INFECTION; PANCREAS DISEASE; PANCREAS TOXICITY; PANCREATITIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; THIOPURINE S METHYLTRANSFERASE DEFICIENCY; THROMBOCYTOPENIA; TPMT GENE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; ULCERATIVE COLITIS; VOMITING;

ADOLESCENT; ADULT; AZATHIOPRINE; CHILD; CHILD, PRESCHOOL; FEMALE; GENOTYPE; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INFLAMMATORY BOWEL DISEASES; MALE; METHYLTRANSFERASES;

EID: 33846136090     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20004     Document Type: Article

References (41)

1. Barabino A, Torrente F, Ventura A, et al. Azathioprine in paediatric inflammatory bowel disease: an Italian multicentre survey. Aliment Pharmacol Ther. 2002;16:1125-1130.
2. Aberra FN, Lichtenstein GR. Review article: monitoring of immunomodulators in inflammatory bowel disease. Aliment Pharmacol Ther. 2005;21:307-319.
3. Lopez-Sanroman A, Bermejo F, Carrera E, et al. Efficacy and safety of thiopurinic immunomodulators (azathioprine and mercaptopurine) in steroid-dependent ulcerative colitis. Aliment Pharmacol Ther. 2004;20:161-166.
4. Bajaj JS, Saeian K. Varma RR, et al. Increased rates of early adverse reaction to azathioprine in patients with Crohn's disease compared to autoimmune hepatitis: a tertiary referral center experience. Am J Gastroenterol 2005;100:1121-1125.
5. Weersma RK, Peters FT, Oostenbrug LE, et al. Increased incidence of azathioprine-induced pancreatitis in Crohn's disease compared with other diseases. Aliment Pharmacol Ther. 2004;20:843-850.
6. Al Hadithy AF, de Boer NK, Derijks LJ, et al. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations. Dig Liver Dis. 2005;37:282-297.
7. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol. 1992;43:329-339.
8. Elion GB, The purine path to chemotherapy. Science. 1989;244:41-47.
9. Krynetski EY, Krynetskaia NF, Gallo AE, et al. A novel protein complex distinct from mismatch repair binds thioguanylated DNA. Mol Pharmacol. 2001;59:367-374.
10. Lennard L. TPMT in the treatment of Crohn's disease with azathioprine. Gut. 2002;51:143-146.
11. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest. 2003;111:1133-1145.
12. Schwab M, Schaffeler E, Marx C, et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics. 2002;12:429-436.
13. Stocco G, Martelossi S, Barabino A, et al. TPMT genotype and the use of thiopurines in paediatric inflammatory bowel disease. Dig Liver Dis. 2005;37:940-945.
14. Marinaki AM, Duley JA, Arenas M, et al. Mutation in the ITPA gene predicts intolerance to azathioprine. Nucleosides Nucleotides Nucleic Acids. 2004;23:1393-1397.
15. Gearry RB, Barclay ML, Burt MJ, et al. Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18:395-400.
16. Gearry RB, Roberts RL, Barclay ML, et al. Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine. Pharmacogenetics. 2004;14:779-781.
17. Hobara N, Watanabe A. Impaired metabolism of azathioprine in carbon tetrachloride-injured rats. Hepatogastroenterology. 1981;28:192-194.
18. Kaplowitz N. Enzymatic thiolysis of azathioprine in vitro. Biochem Pharmacol. 1976;25:2421-2426.
19. Kaplowitz N, Kuhlenkamp J. Inhibition of hepatic metabolism of azathioprine in vivo. Gastroenterology. 1978;74:90-92.
20. Cara CJ, Pena AS, Sans M, et al. Reviewing the mechanism of action of thiopurine drugs: towards a new paradigm in clinical practice. Med Sci Monit. 2004;10:RA247-254.
21. Kraus P, Kloft HD. The activity of glutathione-S-transferases in various organs of the rat. Enzyme. 1980;25:158-160.
22. Rahman SH, Ibrahim K, Larvin M, et al. Association of antioxidant enzyme gene polymorphisms and glutathione status with severe acute pancreatitis. Gastroenterology. 2004;126:1312-1322.
23. Townsend DM, Tew KD. The role of glutathione-S-transferase in anticancer drug resistance. Oncogene. 2003;22:7369-7375.
24. Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol. 2005;45:51-88.
25. Cotton SC, Sharp L, Little J, et al. Glutathione S-transferase polymorphisms and colorectal cancer: a HuGE review. Am J Epidemiol. 2000;151:7-32.
26. Welfare M, Monesola Adeokun A, Bassendine MF, et al. Polymorphisms in GSTP1, GSTM1, and GSTT1 and susceptibility to colorectal cancer. Cancer Epidemiol Biomarkers Prev. 1999;8:289-292.
27. Verlaan M, te Morsche RH, Roelofs HM, et al. Glutathione S-transferase Mu null genotype affords protection against alcohol induced chronic pancreatitis. Am J Med Genet A. 2003;120:34-39.
28. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology. 2000;118:1025-1030.
29. Ansari A, Hassan C, Duley J, et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther. 2002;16:1743-1750.
30. Chen CL, Liu Q, Pui CH, et al. Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia. Blood. 1997;89:1701-1707.
31. Stocco G, Martelossi S, Barabino A, et al. TPMT genotype and the use of thiopurines in paediatric inflammatory bowel disease. Dig Liver Dis. 2005.
32. Hayes JD, Strange RC. Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology. 2000;61:154-166.
33. Kaplowitz N. Interaction of azathioprine and glutathione in the liver of the rat. J Pharmacol Exp Ther. 1977;200:479-486.
34. DeLeve LD, Wang X, Kuhlenkamp JF, et al. Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic venoocclusive disease. Hepatology. 1996;23:589-599.
35. Tapner MJ, Jones BE, Wu WM, et al. Toxicity of low dose azathioprine and 6-mercaptopurine in rat hepatocytes. Roles of xanthine oxidase and mitochondrial injury. J Hepatol, 2004;40:454-463.
36. Lee AU, Farrell GC. Mechanism of azathioprine-induced injury to hepatocytes: roles of glutathione depletion and mitochondrial injury. J Hepatol. 2001;35:756-764.
37. Cheok MH, Evans WE. Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat Rev Cancer. 2006;6:117-129.
38. Floyd A, Pedersen L, Nielsen GL, et al. Risk of acute pancreatitis in users of azathioprine: a population-based case-control study. Am J Gastroenterol. 2003;98:1305-1308.
39. McCarver DG, Hines RN. The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J Pharmacol Exp Ther. 2002;300:361-366.
40. Strange RC, Davis BA, Faulder CG, et al. The human glutathione S-transferases: developmental aspects of the GST1, GST2, and GST3 loci. Biochem Genet. 1985;23:1011-1028.
41. Menor C, Fernandez-Moreno MD, Fueyo JA, et al. Azathioprine acts upon rat hepatocyte mitochondria and stress-activated protein kinases leading to necrosis: protective role of N-acetyl-L-cysteine. J Pharmacol Exp Ther. 2004;311:668-676.